Year: 2022

Rovio Entertainment Corporation         Stock Exchange Release         December 28, 2022 at 11:30 a.m. EET Rovio completes its share buyback programme As communicated on November 8, 2022 the Board of Directors of Rovio Entertainment decided to use the authorisation given by the Annual General Meeting held on April 7, 2022 to repurchase the company’s own shares. The repurchases started on November 9, 2022 and ended on December 27, 2022. During this period, Rovio repurchased 1,000,000 shares for a total cost of EUR 6,075,121.50, yielding an average price of EUR 6.075122 per share, corresponding to approximately 1.2% of the total number of the company’s shares, which is 82,963,825. The repurchased shares are to be used to develop the Company’s capital structure and/or to use the shares as consideration in potential acquisitions, as part of...

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE28 DECEMBER 2022 at 9.30 EEST          40,443 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 40,443 A shares have been converted into 40,443 B shares. The conversion has been entered into the Trade Register on 28 December 2022. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,186,494 A shares and 106,947,784 B shares. The number of votes of the company’s shares is after the conversion 790,677,664. Orion CorporationJari Karlson CFO     Olli Huotari SVP, Corporate Functions                                                  Contact person:Tuukka Hirvonen, Investor Relations,...

Pixium Vision welcomes judgment by Paris Commercial Court against Second Sight Medical ProductsCourt finds Second Sight Medical Products breached 2021 contractual obligations to Pixium Vision Court orders Second Sight Medical Products to pay Pixium Vision an additional €1.58 million in costs and damagesParis, France, December 28, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, today announces that the company welcomes the judgment rendered by the Paris Commercial Court in the case brought by Pixium Vision against Second Sight Medical Products, Inc. (renamed Vivani Medical, Inc.) following the latter’s withdrawal from the proposed business...

Basel/Allschwil, Switzerland, December 28, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has fully repaid its 2.75% convertible bonds (ISIN CH0305398148), which were due on December 23, 2022, with an outstanding nominal amount of CHF 113.8 million. As there was no conversion, no shares have been issued and the share capital remains unchanged. Adesh Kaul, Chief Financial Officer, stated: “We are very pleased to have fully redeemed the 2022 convertible bonds. As announced, we have thus successfully reduced our debt-level without diluting our shareholders, based on the growing cash flows from our marketed drugs and our strong financial prospects.” About Basilea Basilea is a commercial-stage...

New York, Dec. 27, 2022 (GLOBE NEWSWIRE) — Mercurity Fintech Holding Inc. (the “Company,” “we,” “us,” “our company,” or “MFH”) (Nasdaq: MFH), a digital fintech group powered by blockchain technology, today announced that on December 23, 2022, in connection with its private investment in public equity financing (the “PIPE”), it entered into a Securities Purchase Agreement (the “SPA”) with an accredited non-U.S. investor to offer and sell the Company’s units, each consisting of one ordinary share and three Warrants (each, a “Warrant” and collectively, the “Warrants”) for total gross proceeds of $5 million (the “Proceeds”). The closing of this third PIPE financing together with the consummation of the first and second PIPE financing would yield total gross proceeds of $13.15 million invested in the Company’s shares and warrants by...

SANTA CLARA, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) — Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has entered into a share purchase agreement for the sale of 146,627,565 shares (subject to adjustment for any stock split occurring prior to closing) of its common stock in a private placement, led by Accelmed, with participation by New Enterprise Associates, at an offering price of $0.2046 per share (subject to adjustment for any stock split occurring prior to closing). Following the offering, Accelmed will become the controlling stockholder of Minerva Surgical. Gross proceeds of the private placement are expected to be approximately $30 million, before deducting placement agent fees and other...

Palm Beach, FL, Dec. 27, 2022 (GLOBE NEWSWIRE) — PMV Consumer Acquisition Corp. (OTC Pink: PMVC) (“PMV” or the “Company”) announced today the completion of the redemption of its outstanding shares of Class A Common Stock subject to redemption, totaling 2,046,609 shares issued in its IPO (“Class A IPO Shares”), in accordance with the provisions of its charter. Holders representing a total of 2,042,409 shares of the Class A IPO Shares called for redemption elected to receive a pro rata share of the cash, including the interest earned thereon net of interest that may be used by the Company to pay its taxes payable (and not any stock), held in the Company’s IPO Trust Account.  The $10.10 per share pro rata amount was calculated by dividing the number of Class A IPO Shares redeemed from each such holder by the total number of outstanding...

First win in region affirms globalization strategy, initially targeting Europe, the Middle East and North Africa as company accelerates global expansion efforts TAIPEI, Taiwan and NEW YORK, Dec. 27, 2022 (GLOBE NEWSWIRE) — Gorilla Technology Group Inc. (“Gorilla”) (NASDAQ: GRRR), a global provider of AI based edge video analytics, IoT technologies, and cybersecurity, today announced that a government agency of a Middle Eastern country developing Smart Cities has communicated its intent to engage Gorilla to implement an expansive cybersecurity solution for one or more cities under development. Gorilla is negotiating final details, and expects to execute a contract and begin implementation in the first half of 2023. The anticipated project is a strong addition to the Company’s 2023 revenue forecast. This deal represents Gorilla’s...